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a  b  s  t  r  a  c  t
Increased longevity has made progression in the number of fractures increasingly signiﬁ-
cant.  Because hip fractures give rise to high morbidity and mortality rates and have high
treatment costs, their occurrence is the most important marker of effectiveness in relation
to  osteoporosis treatment. In countries and systems that, especially over the last decade,
have been investing in the prevention of osteoporosis and its consequences, the number of
hip  fractures has been decreasing. What these countries have in common is secondary pre-
vention of fractures, i.e. to avoid subsequent fractures. Given that half of the patients who
present hip fractures have had a previous fracture and that the treatments available have
proven to be extremely efﬁcient for decreasing subsequent fractures, a good proportion of
hip  fractures are preventable. It is within this scenario that orthopedists play a leading role.
©  2016 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved.
Para  que  a  primeira  fratura  seja  a  última
alavras-chave:
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raturas ósseas
raturas por osteoporose
r  e  s  u  m  o
O aumento da longevidade faz com que a progressão do número de fraturas seja cada vez
mais  expressiva. A ocorrência da fratura do quadril, pela sua alta taxa de mortalidade e
morbidade e pelo alto custo de tratamento, é o mais importante marcador da efetividade
no  tratamento da osteoporose. Em países e sistemas que, especialmente na última década,
vêm investindo na prevenc¸ão da osteoporose e de suas consequências, o número de frat-
uras do quadril vem diminuindo. O que eles têm em comum é a prevenc¸ão secundária de
fraturas, ou seja, evitar a fratura seguinte. Visto que metade dos pacientes que tiveram uma
fratura do quadril teve uma fratura prévia e que os tratamentos disponíveis provaram serextremamente eﬁcientes para diminuir fraturas subsequentes, boa parte das fraturas dequadril é evitável. É nesse
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Introduction
Osteoporosis is deﬁned as a bone disease characterized by
impairment of bone resistance, which predisposes toward
increased risk of fractures.1,2
Fractures due to bone fragility are the greatest clinical
expression of this disease.
Fractures due to fragility are deﬁned by the World Health
Organization as “fractures caused by trauma that would be
insufﬁcient to fracture normal bone and which results from
reduced resistance to compression or torsion”.3
From a clinical point of view, these fractures can be
deﬁned as resulting from minimal trauma, such as falling
from a standing position or less than this, or by unidentiﬁed
trauma. Fractures due to fragility typically include vertebral,
proximal femoral (hip), distal radial and proximal humeral
fractures.4
Fractures due to fragility are the strongest indicator or a
risk of future fractures. Patients who have had a fracture at
any site present approximately twice the risk of having a frac-
ture in the future, in comparison with individuals who have
never had such injuries. Patients with fractures due to low-
energy trauma to the wrist, hip, proximal humerus or ankle
present a risk of future fractures that is almost four times
greater. Patients with a vertebral fracture will have new verte-
bral fractures within the next three years, and many will have
them within the ﬁrst of these years.5–7
Patients with vertebral fractures present a risk of having
similar injuries in the future that is almost ﬁve times higher,
and a risk of having hip fractures and other non-vertebral frac-
tures that is twice as high. Patients who  suffer wrist fractures
present a relative risk of having hip fractures in the future that
is almost twice as high.5–7
Secondary fractures occur rapidly after the ﬁrst fracture.
The risk of subsequent fractures seems to be higher just after
a fracture, especially in the ﬁrst year.5–7
Patients who have suffered a hip fracture form a group at
higher risk of having fractures in the future. They need to be
prioritized for assessment and for starting treatments, so as
to avoid other secondary fractures.8–10
Contrary to what might be imagined, these patients can
beneﬁt greatly from treatment.11,12
Initiatives for avoiding secondary (subsequent) fractures
should be offered to all men  and women over the age of 50
years who  have had fractures due to fragility, since these
fractures may precede hip fractures in a cycle in which one
fracture leads to another, in a “cascade” of fractures.13–15
An initial fracture due to fragility is sufﬁcient for request-
ing an evaluation that includes measurement of bone mineral
density, with evaluation of the risk of fractures, and for start-
ing the treatment if there is no formal contraindication.16,17
Studies with the highest level of evidence have shown that
osteoporosis can be treated, thus diminishing the likelihood
of fractures in the future.17
Around 50% of all cases of hop fracture are concentrated
in 16% of the postmenopausal female population, with histo-
ries of fractures. Therefore, secondary prevention presents an
opportunity for intervention in around half of all hip fracture
patients.18,191 6;5 1(2):121–126
The  impact  of  fractures  due  to  fragility
In Brazil, the number of people affected by fractures due
fragility reaches 10 million and the expenditure on treating
and caring for these cases within the National Health Sys-
tem (SUS) is high. In 2010 alone, around R$ 81 million was
spent within SUS on attending to patients with osteoporosis
and who had suffered falls and fractures.20
It has been estimated that the number of hip fractures per
year in Brazil, which was around 121,700 in 2010, will reach
160,000 by 2050.21,22
A recent study conducted by the Mayo Clinic showed that
between 2000 and 2011, there were 4.9 million hospital admis-
sions due to osteoporotic fractures, 2.9 million due to acute
myocardial infarction (AMI), three million due to stroke and
700,000 due to breast cancer. Osteoporotic fractures accounted
for more than 40% of the hospital admissions among these
four types of admission, and for the length of hospital stay.
The hospital cost was greater for osteoporotic fractures (US$
5.1 billion) than for AMI  (US$ 4.3 billion), stroke (US$ 3 billion)
or breast cancer (US$ 0.5 billion).23
Drug  treatments
Drugs for treating osteoporosis can be divided into two  groups:
(1) inhibitors of bone reabsorption, which work through
blocking the action of osteoclasts. These consist of bisphos-
phonates, selective estrogen receptor modulators (SERMs),
calcitonin, estrogen and denosumab and (2) activators of
bone formation, which work as anabolic agents, thus increas-
ing bone metabolism, with predominance of bone formation
through stimulation of osteoblasts. These comprise parathy-
roid hormone (PTH), teriparatide (which is similar to PTH),
growth hormone (GH) and active metabolites of vitamin D
(alphacalcidol and calcitriol).
Strontium ranelate presents a double mode of action, in
that it both inhibits reabsorption and stimulates bone forma-
tion.
Bisphosphonates reduce occurrences of vertebral and non-
vertebral fractures by 40–50%. They are indicated both for
women and for men, and in cases of secondary osteoporosis
induced through corticoids.24,25
They are available in oral and injectable forms in various
frequencies of dosage: daily, weekly, monthly, three-monthly
and annual use.
Raloxifene is the SERM most used for preventing and treat-
ing osteoporosis. Over a three-year evaluation on women with
osteoporosis, there was an increase in bone mineral density
in the spine and femoral neck, with a reduction in the risk of
vertebral fractures.26,27
Calcitonin is available in as a nasal spray or in subcu-
taneous form for daily use. It gives rise to a reduction in
occurrences of vertebral fractures in 36% of the patients,
but without any reduction in hip fractures or any  signiﬁcant
change in either bone mineral density or bone metabolism.28
Estrogen replacement therapy is indicated for preventive
treatment of osteoporosis. The risks and beneﬁts of this
 0 1 6
o
g
t
f
s
c
t
c
e
f
f
w
d
p
m
b
n
d
a
w
a
w
d
w
t
b
s
f
h
P
P
o
l
o
b
o
w
t
a
t
r
m
d
c
V
n
i
G
D
fr e v b r a s o r t o p . 2
ption need to be discussed between the patient and her
ynecologist.29
Denosumab is a monoclonal antibody that has been found
o reduce the incidence of new vertebral fractures and hip
ractures in postmenopausal women who  are at high risk of
uffering fractures. Its convenient form of dosage (a single sub-
utaneous application every six months) facilitates adherence
o the treatment.30
The active metabolites of vitamin D (calcitriol and alpha-
alcidol) increase calcium absorption. They may have a direct
ffect on bone cells and may also reduce the incidence of
ractures. Active derivatives of vitamin D have been indicated
or use among debilitated elderly people with osteoporosis
ho  are reclusive and have little exposure to the sun, at a
ose of 0.5 mcg/day. However, the results relating to fracture
revention are not uniform. Alphacalcidol may diminish the
yopathy consequent to aging.31,32
Teriparatide (PTH) has an anabolic effect. It stimulates
one reabsorption and formation, acts on the coupling mecha-
ism of bone remodeling, promotes large gains of bone mass,
iminishes the risk of vertebral and non-vertebral fractures
nd increases the bone mass of vertebrae, femurs and the
hole body. Its use is safe and well tolerated, both for men
nd for women. It is indicated in cases of severe osteoporosis
ith fractures: it has a major effect on osteoporosis induced
ue to corticoids and the effects persist for six months after
ithdrawal. Recent studies have shown that it can be used for
wo years. Beyond that point, the therapy can continue with
isphosphonates or denosumab.33,34
Strontium ranelate acts both to inhibit reabsorption and to
timulate bone formation. It has been shown to be effective
or reducing the occurrences of vertebral, non-vertebral and
ip fractures.35–37
hysical  activity,  calcium  and  vitamin  D
eak maturation of the skeleton is attained between the ages
f 20 and 30 years. With adequate nutrition and the normal
evels of physical activity available to everyone, higher levels
f bone mass can be attained. This forms a calcium reserve
ank from which the deposits will be spent during the period
f aging, thus delaying or impeding osteoporosis, especially in
omen. During growth, the skeleton gains bone helps to main-
ain the bone mass that has been acquired and, during the
ging process, this diminishes the losses, maintains muscle
onus and aids in diminishing the number of falls.38,39
All patients presenting bone loss, or who are potentially at
isk of losses, should be counseled to include calcium and vita-
in  D in their diets, or as supplements. Calcium absorption
ecreases with age. Around 75% of the calcium ingested by
hildren is absorbed, while only 30–50% is absorbed in adults.
itamin D activates calcium absorption in the intestine and it
eeds to be supplemented in elderly, sedentary or hospitalized
ndividuals.40
aps  in  treatmentespite substantial evidence that previous occurrence of a
racture results in increased risk of a subsequent fracture,;5 1(2):121–126 123
fewer than 30% of postmenopausal women and fewer than
10% of men  with previous fractures are treated.41,42
Independent of the availability of medications that reduce
the risk of repeated fractures by 25–70%, the majority of
patients with incidental osteoporotic fractures are neither
investigated nor treated.43,44
Current practices have the result that 80% of patients with
fractures due to fragility are neither evaluated nor treated for
osteoporosis or for prevention of falls so as to reduce the future
incidence of fractures. The consequence of this gap in treat-
ments is that very many  fractures occur but could have been
avoided. These are an afﬂiction among elderly people and cost
millions of dollars around the world.45,46
Secondary  prevention
Treatments that are started early on, after a primary frac-
ture, may diminish recurrent fracture rates by between 30 and
60%.47,48
Anti-osteoporosis treatment implemented after repair
treatment for a hip fracture caused by minimal trauma has
been correlated with a reduced rate of new clinical fractures
and with lower mortality and longer survival.12,49–51
Patients who have suffered a hip fracture are the group at
highest risk of subsequent fractures. Priority needs to be given
to starting their treatment, in order to avoid secondary frac-
tures. Contrary to common assumptions, these patients may
beneﬁt greatly from this treatment.
Several studies have shown that persistence with and
adherence to osteoporosis treatment is poor, and that this
results in less-than-ideal effectiveness (under real treatment
conditions). Non-adherent patients have been found to have
more  comorbidities, be more  frail and have higher healthcare
expenditure.13,52–54
For each environment reported, a fracture liaison service
(FLS) is the most effective tool. The FLS is a service dedicated to
treating patients subsequent to fractures due to fragility. This
is perhaps the only effective means for achieving a change
in the current panorama. This approach creates a contin-
uum of care and makes it possible to surmount the gaps in
investigation and intervention subsequent to fractures and
the unnecessarily high incidence of fractures thereafter.
The FLS in Glasgow has already attended more  than a mil-
lion people since the turn of the century. A cost-effectiveness
analysis has shown that for every 10,000 patients attended
through the FLS, in comparison with ordinary attendance
in the United Kingdom, 18 cases of fractures were avoided,
including 11 cases of hip fracture, with savings equivalent to
33,600 dollars.55,56
The Healthy Bones program run by the health insur-
ance company Kaiser Permanente is the biggest program for
preventing fractures due to fragility in the world. It is con-
ducted by orthopedists and is highly focused on reducing the
incidence of fractures by 20% over a ﬁve-year period. The pro-
gram began with hip fractures alone and, as its effectiveness
became proven, more  resources were injected, such that it now
acts in relation to both secondary and primary prevention. In
2009, after seven years of the program integrated with Kaiser’s
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eleven medical centers in southern California, the hip fracture
reduction rate had surpassed 40%.57–59
Prevrefrat  –  the  Brazilian  experience
Prevrefrat (Programa de Prevenc¸ão a Refraturas, i.e. repeated
fracture prevention program) is a service destined for treat-
ing patients who have had fractures caused by low-intensity
trauma such as falling from a standing position, consequent
to osteoporosis.
It has been in operation for almost four years and, since
2013, it has been a worldwide reference point for prevention
of new fractures.
Through its coordinator, Prevrefrat has disseminated a phi-
losophy of secondary fracture prevention and has decisively
helped in implementing other services throughout Brazil.
Prevrefrat is one of the most respected FLS in the world,
and is classiﬁed as a gold standard, as demonstrated in Fig. 1.
Methodology  of  Prevrefrat
The ﬁrst consultation consists of a brief interview to ascertain
whether the case ﬁts within the program. The next step is to
register the individuals within the program, through gathering
data relating to their medical history, their lifestyle habits and
the fracture that occurred.
After this, lateral radiographs of the fracture and of the dor-
sal and lumbar spine are produced, and bone densitometry is
measured.Laboratory tests are requested: calcium, creatinine, 25(OH)
vitamin D and PTH, and possibly others if needed. Another
consultation is scheduled, on average four weeks later, in order
to assess the tests.
Fig. 1 – Map  of good practices from the Capture the Fracture c
Source: http://www.capture-the-frac1 6;5 1(2):121–126
If a secondary cause is detected, the patient is referred
to other specialists. In cases of osteopenia or primary osteo-
porosis, and if there is no contraindication, an annual venous
infusion of zoledronic acid is administered, or denosumab is
applied subcutaneously if the creatinine clearance is less than
35.
Supplementation of calcium and vitamin D is also applied,
in accordance with the criteria established through the inter-
national guidelines.
At the physician’s discretion, a DVD containing 14 exercises
to be performed at home is provided. The next consultation is
scheduled for three weeks afterwards, on average. In the ﬁrst
year, the consultations take place every three months and,
after this, they become half-yearly.
In the clinical proﬁle for Prevrefrat, injectable drugs that are
administered once a year or half-yearly (supplied by the Fed-
eral Hospital of Ipanema) are speciﬁed. This is because of the
extremely low degree of adherence to oral drugs: more  than
70% of such patients do not complete one year of treatment.
Poor adherence has a decisive negative inﬂuence on the out-
come with regard to avoidance of new fractures. The severity
of our patients’ clinical condition does not allow use of drugs
with this proﬁle of low adherence.
Studies presented at the International Osteoporosis Foun-
dation World Congress of 2014 demonstrated adherence rates
of 100% among patients with hip fractures and 85% among
those with non-hip fractures.
The results that follow prove that this option is correct and
effective.Results  from  Prevrefrat
Over a period of three years and ten months, 450 patients were
followed up and 12 cases of fractures occurred. None of these
ampaign of the International Osteoporosis Foundation.
ture.org/map-of-best-practice.
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ere hip fractures. In other words, the rate of reduction of
ubsequent fractures was more  than 97%.
thical  dimension  of  secondary  prevention  of
ractures
lder patients usually present with their ﬁrst fracture at an
mergency service, or go to an orthopedist who has the skills
nd expertise to manage the acute condition and repair the
racture. However, there is an additional dimension: know-
ng that the fracture occurred in an individual with low bone
esistance identiﬁes this person as presenting higher risk of
uture fractures. Studies with the highest level of evidence
ave shown that osteoporosis can be managed to diminish the
ikelihood of future fractures. The data clearly demonstrate
hat a high proportion of secondary fractures can be avoided
hrough appropriate management and that an initial fracture
ue to fragility is reason enough to ask for a complete eval-
ation, including measurement of bone mineral density and
valuation of the risk, and is enough for starting treatment.
It might be argued that in many  cases, neither the ortho-
edist nor the emergency physician is the ideal person for
tarting this investigation and treatment. However, this does
ot absolve them from the responsibility for ensuring that the
atient or the patient’s family is fully aware of the risk and for
eferring the patient for appropriate evaluation and follow-up.
The underlying bone fragility and the increased risk of
ractures can be managed subsequently by orthopedists,
ndocrinologists, rheumatologists, geriatricians and other
ealthcare professionals, along with collaboration from pro-
essionals involved in the rehabilitation process.
The data are sufﬁciently convincing to characterize appro-
riate referral as an obligation to do the right thing, i.e. to
rovide the way forward to the best result. Any conduct dif-
ering from this will certainly be below the acceptable ethical
nd clinical standards.60
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. Osteoporosis prevention, diagnosis, and therapy. NIH
Consens Statement. 2000;17(1):1–45.
2. NIH Consensus Development Panel on Osteoporosis
Prevention. Diagnosis and therapy. Osteoporosis prevention,
diagnosis, and therapy. JAMA. 2001;285(6):785–95.
3. Guidelines for preclinical evaluation and clinical trials in
osteoporosis. Geneva: World Health Organization; 1998.
4. Brown JP, Josse RG. Clinical practice guidelines for the
diagnosis and management of osteoporosis in Canada. CMAJ.
2002;167 10 Suppl:S1–34.
5. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I,
Petterson C, et al. Fracture risk following an osteoporotic
fracture. Osteoporos Int. 2004;15(3):175–9.
6. Lauritzen JB, Lund B. Risk of hip fracture after osteoporosis
fractures. 451 women with fracture of lumbar spine,
2;5 1(2):121–126 125
olecranon, knee or ankle. Acta Orthop Scand.
1993;64(3):297–300.
7. Dreinhöfer KE, Féron JM, Herrera A, Hube R, Johnell O, Lidgren
L,  et al. Orthopaedic surgeons and fragility fractures. A survey
by  the Bone and Joint Decade and the International
Osteoporosis Foundation. J Bone Joint Surg Br.
2004;86(7):958–61.
8. Lönnroos E, Kautiainen H, Karppi P, Hartikainen S, Kiviranta I,
Sulkava R. Incidence of second hip fractures. A
population-based study. Osteoporos Int. 2007;18(9):1279–85.
9. Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B. Short
time-frame from ﬁrst to second hip fracture in the Funen
County Hip Fracture Study. Osteoporos Int. 2006;17(9):1353–7.
0. Lawrence TM, Wenn R, Boulton CT, Moran CG. Age-speciﬁc
incidence of ﬁrst and second fractures of the hip. J Bone Joint
Surg Br. 2010;92(2):258–61.
1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA,
et  al.; Horizon Pivotal Fracture Trial. Once-yearly zoledronic
acid for treatment of postmenopausal osteoporosis. N Engl J
Med. 2007;356(18):1809–22.
2. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper
CF, Mautalen C, et al.; HORIZON Recurrent Fracture Trial.
Zoledronic acid and clinical fractures and mortality after hip
fracture. N Engl J Med. 2007;357(18):1799–809.
3. Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J.
Osteoporotic fracture: missed opportunity for intervention.
Osteoporos Int. 2003;14(9):780–4.
4. Edwards BJ, Bunta AD, Simonelli C, Bolander M,  Fitzpatrick
LA. Prior fractures are common in patients with subsequent
hip fractures. Clin Orthop Relat Res. 2007;461:226–30.
5. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd,
Berger M. Patients with prior fractures have an increased risk
of future fractures: a summary of the literature and statistical
synthesis. J Bone Miner Res. 2000;15(4):721–39.
6. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P,
et  al. A meta-analysis of previous fracture and subsequent
fracture risk. Bone. 2004;35(2):375–82.
7. Cranney A, Guyatt G, Grifﬁth L, Wells G, Tugwell P, Rosen C,
et  al. Meta-analyses of therapies for postmenopausal
osteoporosis. IX: summary of meta-analyses of therapies for
postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570–8.
8. British Orthopaedic Association. The care of patients with
fragility fracture; 2007. Available from: http://www.fractures.
com/pdf/BOA-BGS-Blue-Book.pdf.
9. Department of Health in England. Prevention Package for
Older People. Available from: http://www.dh.gov.uk/en/
Publicationsandstatistics/Publications/DH 103146.
0.  Prevenc¸ão à osteoporose deve comec¸ar na infância. Available
from: http://portalsaude.saude.gov.br/index.php/cidadao/
principal/saude-em-dia/mais-sobre-saude-em-dia.
1.  Pinheiro MM, Reis Neto ET, Machado FS, Omura F, Yang JH,
Szejnfeld J, et al. Risk factors for osteoporotic fractures and
low bone density in pre and postmenopausal women. Rev
Saude Publica. 2010;44(3):479–85.
2. Martini LA, Moura EC, Santos LC, Malta DC, Pinheiro MM.
Prevalência de diagnóstico autorreferido de osteoporose,
Brasil, 2006. Rev Saude Publica. 2009;43 Suppl 2:107–16.
3. Singer A, Exuzides A, Spangler L, O’Malley C, Colby C,
Johnston K, et al. Burden of illness for osteoporotic fractures
compared with other serious diseases among
postmenopausal women in the United States. Mayo Clin Proc.
2015;90(1):53–62.
4. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T,
Hochberg MC, et al. Fracture Intervention Trial. Fracture risk
reduction with alendronate in women with osteoporosis: the
Fracture Intervention Trial. FIT Research Group. J Clin
Endocrinol Metab. 2000;85(11):4118–24.
5. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T,
Keller M, et al. Effects of risedronate treatment on vertebral
p . 2 0 
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
McLellan A, et al. ASBMR Task Force on Secondary Fracture
Prevention. Making the ﬁrst fracture the last fracture: ASBMR126  r e v b r a s o r t o 
and nonvertebral fractures in women with postmenopausal
osteoporosis: a randomized controlled trial. Vertebral Efﬁcacy
With  Risedronate Therapy (VERT) Study Group. JAMA.
1999;282(14):1344–52.
6. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R,
Mitlak BH, et al. Long-term effects of raloxifene on bone
mineral density, bone turnover, and serum lipid levels in
early postmenopausal women: three-year data from 2
double-blind, randomized, placebo-controlled trials. Arch
Intern Med. 2000;160(22):3444–50.
7. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen
T,  Genant HK, et al. Reduction of vertebral fracture risk in
postmenopausal women with osteoporosis treated with
raloxifene: results from a 3-year randomized clinical trial.
Multiple Outcomes of Raloxifene Evaluation (More)
Investigators. JAMA. 1999;282(7):637–45.
8. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona
A, Harris S, et al. A randomized trial of nasal spray salmon
calcitonin in postmenopausal women with established
osteoporosis: the prevent recurrence of osteoporotic fractures
study. Proof Study Group. Am J Med. 2000;109(4):267–76.
9. The Writing Group for the PEPI. Effects of hormone therapy
on  bone mineral density: results from the postmenopausal
estrogen/progestin interventions (PEPI) trial. JAMA.
1996;276(17):1389–96.
0. Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K,
Törring O, et al. Treatment with denosumab reduces the
incidence of new vertebral and hip fractures in
postmenopausal women at high risk. J Clin Endocrinol Metab.
2011;96(6):1727–36.
1. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J
Med. 1998;338(11):736–46.
2. Guarniero R, Oliveira LG. Osteoporose: atualizac¸ão no
diagnóstico e princípios básicos para o tratamento. Rev Bras
Ortop. 2004;39(9):477–85.
3. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA,
Reginster JY, et al. Effect of parathyroid hormone (1–34) on
fractures and bone mineral density in postmenopausal
women  with osteoporosis. N Engl J Med. 2001;344(19):1434–41.
4. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud
CD. Bone mass continues to increase at the hip after
parathyroid hormone treatment is discontinued in
glucocorticoid-induced osteoporosis: results of a randomized
controlled clinical trial. J Bone Miner Res. 2000;15(5):944–51.
5. Reginster JY, Spector T, Badurski J. A short-term run-in study
can  signiﬁcantly contribute to increasing the quality of
long-term osteoporosis trials. The strontium ranelate phase
III  program. Oteoporos Int. 2002;13 Suppl 1:S30.
6. Meunier PJ, Roux C, Ortolani S. Strontium ranelate reduces
the vertebral fracture risk in women with postmenopausal
osteoporosis. Osteoporos Int. 2002;13 Suppl 1:045.
7. Reginster JY. Strontium ranelate reduces the risk of hip
fracture in women with postmenopausal osteoporosis.
Osteoporos Int. 2002;13 Suppl 1:014.
8. Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA. A
six-year longitudinal study of the relationship of physical
activity to bone mineral accrual in growing children: the
university of Saskatchewan bone mineral accrual study. J
Bone Miner Res. 1999;14(10):1672–9.
9. Plapler PG, Rocco JCP. Osteoporose e exercícios. Acta Ortop
Bras. 1998;6(1):49–54.
0. National Osteoporosis Foundation (NOF). Osteoporosis
Prevention Strategies. Osteoporosis Clinical Updates. 1996.
1. Brianc¸on D, de Gaudemar JB, Forestier R. Management of
osteoporosis in women with peripheral osteoporotic fractures
after 50 years of age: a study of practices. Joint Bone Spine.
2004;71(2):128–30.1 6;5 1(2):121–126
2. McCloskey E, de Takats D, Orgee J. Characteristics associated
with non-persistence during daily therapy. Experience from
the  placebo wing of a community based clinical trial. J Bone
Miner Res. 2005;20 Suppl 1:S282.
3. Kleerekoper M, Gold DT. Osteoporosis prevention and
management: an evidence-based review. Clin Obstet Gynecol.
2008;51(3):556–63.
4. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi
JD.  Fragility fractures and the osteoporosis care gap: an
international phenomenon. Semin Arthritis Rheum.
2006;35(5):293–305.
5. Hooven F, Gehlbach SH, Pekow P, Bertone E, Benjamin E.
Follow-up treatment for osteoporosis after fracture.
Osteoporos Int. 2005;16(3):296–301.
6. Peng EW,  Elnikety S, Hatrick NC. Preventing fragility hip
fracture in high risk groups: an opportunity missed. Postgrad
Med  J. 2006;82(970):528–31.
7. Smith MG, Dunkow P, Lang DM. Treatment of osteoporosis:
missed opportunities in the hospital fracture clinic. Ann R
Coll Surg Engl. 2004;86(5):344–6.
8. Vaile J, Sullivan L, Bennett C, Bleasel J. First Fracture Project:
addressing the osteoporosis care gap. Intern Med J.
2007;37(10):717–20.
9. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of
osteoporosis treatment on mortality: a meta-analysis. J Clin
Endocrinol Metab. 2010;95(3):1174–81.
0. Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell
NR, Juby AG, et al. Oral bisphosphonates are associated with
reduced mortality after hip fracture. Osteoporos Int.
2011;22(3):983–91.
1. Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM,
Cumming RG, et al. Oral bisphosphonates are associated with
reduced mortality in frail older people: a prospective ﬁve-year
study. Osteoporos Int. 2011;22(9):2551–6.
2. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ.
Systematic review and meta-analysis of real-world adherence
to drug therapy for osteoporosis. Mayo Clin Proc.
2007;82(12):1493–501.
3. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic
review of persistence and compliance with bisphosphonates
for osteoporosis. Osteoporos Int. 2007;18(8):1023–31.
4. Hopman WM,  Berger C, Joseph L, Towheed T, Prior JC,
Anastassiades T, et al. Health-related quality of life in
Canadian adolescents and young adults: normative data
using the SF-36. Can J Public Health. 2009;100(6):449–52.
5. McLellan AR, Gallacher SJ, Fraser M,  McQuillian C. The
fracture liaison service: success of a program for the
evaluation and management of patients with osteoporotic
fracture. Osteoporos Int. 2003;14(12):1028–34.
6. McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM,  Lock S,
McCrink L, et al. Fracture liaison services for the evaluation
and management of patients with osteoporotic fracture: a
cost-effectiveness evaluation based on data collected over 8
years of service provision. Osteoporos Int. 2011;22(7):2083–98.
7. Dell R. Fracture prevention in Kaiser Permanent Southern
California. Osteoporos Int. 2011;22 Suppl 3:457–60.
8. Dell RM, Greene D, Anderson D, Williams K. Osteoporosis
disease management: what every orthopaedic surgeon
should know. J Bone Joint Surg Am. 2009;91 Suppl 6:79–86.
9. Dell R, Greene D, Schelkun SR, Williams K. Osteoporosis
disease management: the role of the orthopaedic surgeon. J
Bone Joint Surg Am. 2008;90 Suppl 4:188–94.
0. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr,task force report on secondary fracture prevention. J Bone
Miner Res. 2012;27(10):2039–46.
